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Abstract
Background
Antimicrobial resistance is a major issue in the Shigellae, particularly as a specific multi-
drug-resistant (MDR) lineage of Shigella sonnei (lineage III) is becoming globally dominant.
Ciprofloxacin is a recommended treatment for Shigella infections. However, ciprofloxacin-
resistant S. sonnei are being increasingly isolated in Asia and sporadically reported on
other continents. We hypothesized that Asia is a primary hub for the recent international
spread of ciprofloxacin-resistant S. sonnei.
Methods and Findings
We performed whole-genome sequencing on a collection of 60 contemporaneous cipro-
floxacin-resistant S. sonnei isolated in four countries within Asia (Vietnam, n = 11; Bhutan,
n = 12; Thailand, n = 1; Cambodia, n = 1) and two outside of Asia (Australia, n = 19; Ireland,
n = 16). We reconstructed the recent evolutionary history of these organisms and com-
bined these data with their geographical location of isolation. Placing these sequences into
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a global phylogeny, we found that all ciprofloxacin-resistant S. sonnei formed a single
clade within a Central Asian expansion of lineage III. Furthermore, our data show that
resistance to ciprofloxacin within S. sonneimay be globally attributed to a single clonal
emergence event, encompassing sequential gyrA-S83L, parC-S80I, and gyrA-D87Gmuta-
tions. Geographical data predict that South Asia is the likely primary source of these organ-
isms, which are being regularly exported across Asia and intercontinentally into Australia,
the United States and Europe. Our analysis was limited by the number of S. sonnei
sequences available from diverse geographical areas and time periods, and we cannot dis-
count the potential existence of other unsampled reservoir populations of antimicrobial-
resistant S. sonnei.
Conclusions
This study suggests that a single clone, which is widespread in South Asia, is likely driving
the current intercontinental surge of ciprofloxacin-resistant S. sonnei and is capable of
establishing endemic transmission in new locations. Despite being limited in geographical
scope, our work has major implications for understanding the international transfer of anti-
microbial-resistant pathogens, with S. sonnei acting as a tractable model for studying how
antimicrobial-resistant Gram-negative bacteria spread globally.
Author Summary
WhyWas This Study Done?
• Antimicrobial resistance is a major issue in Shigella, and ciprofloxacin is a recommended
treatment for Shigella infections.
• Ciprofloxacin-resistant Shigella sonnei are being increasingly isolated globally.
What Did the Researchers Do and Find?
• We performed genome sequencing on 60 ciprofloxacin-resistant S. sonnei isolated in six
countries within and outside of Asia.
• Placing these genome sequences in context with other strains, we found that all cipro-
floxacin-resistant S. sonnei formed a single clade, with South Asia as the likely primary
source of these organisms.
• These organisms are also being regularly exported across Asia and intercontinentally
into Australia, the United States, and Europe.
• The number of S. sonnei sequences available from other locations limited our analysis.
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What Do These Findings Mean?
• Our work suggests that a single clone, which is widespread in South Asia, is driving the
current global surge of ciprofloxacin-resistant S. sonnei.
• We argue that S. sonnei acts as a tractable model for studying how antimicrobial-resis-
tant, Gram-negative bacteria spread globally.
Introduction
Diarrheal disease is the second most common cause of mortality in children under the age of 5
y worldwide, equating to approximately 800,000 deaths per year [1]. The recent Global Enteric
Multicentre Study (GEMS), a large, prospective, case-control study focusing on mild and severe
paediatric diarrheal illnesses in sub-Saharan Africa and South Asia, found that Shigella (a
genus of Gram-negative enteric bacteria) were amongst the top four most prevalent diarrhoeal
pathogens in these settings [2]. The most recent estimates suggest that Shigella infections
account for around 125 million cases of diarrhoea annually, with the majority occurring in
children in low-income countries [3]. There are four Shigella species (dysenteriae, boydii, flex-
neri, and sonnei), but the overwhelming majority of the current global burden is presently
caused by S. sonnei and S. flexneri. Present-day international epidemiology of the various Shi-
gella species is particularly intriguing, as S. sonnei is replacing S. flexneri as the most common
cause of shigellosis worldwide; this pattern is accentuated in regions undergoing rapid eco-
nomic development [4,5], where S. flexneri dominated as recently as a decade ago.
Shigella infections are characterised by the invasion and disruption of the epithelial cells lin-
ing the gastrointestinal mucosa, resulting in mucous and/or bloody diarrhoeal discharge.
Although shigellosis is typically self-limiting, antimicrobial treatment is used to prevent com-
plications, reduce dysenteric discharge, and curb post-symptomatic faecal shedding [6,7]. Con-
sequently, resistance to antimicrobials restricts treatment options, placing vulnerable
individuals suffering from shigellosis at increased risk of complications and increasing the like-
lihood of protracted faecal shedding. One of the current recommended first-line treatments for
shigellosis is the fluoroquinolone ciprofloxacin [8]. The fluoroquinolones target the DNA gyr-
ase, a type II topoisomerase that is essential for bacterial DNA replication and transcription
[9].
Antimicrobial resistance is an emerging global issue in S. sonnei, with a specific multidrug-
resistant (MDR) lineage (III) now dominating internationally. Furthermore, organisms belong-
ing to lineage III appear to be highly proficient at acquiring resistance to additional antimicro-
bials (including third-generation cephalosporins) when they are introduced into new locations
[10]. However, given their common usage and broad spectrum of activity, resistance against
the fluoroquinolones is the most concerning. Since the first isolation of S. sonnei with reduced
susceptibility to ciprofloxacin in Japan in 1993 [11], ciprofloxacin-resistant S. sonnei have been
increasingly reported throughout Asia [12–14]. Furthermore, public health laboratories in sev-
eral non-Asian countries with low incidences of shigellosis have reported the isolation of cipro-
floxacin-resistant S. sonnei, often from individuals reporting recent travel to locations with a
high risk of shigellosis [15–17].
Whole-genome sequencing has proven to be the gold standard for tracking the interna-
tional dissemination of clonal bacterial pathogens [18,19], and we have previously exploited
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this method to study the phylogenetic structure and spread of S. sonnei at both national and
intercontinental levels [10,20]. Hypothesising that Asia was a hub for the recent interna-
tional spread of ciprofloxacin-resistant S. sonnei, we performed whole-genome sequencing
and phylogenetic characterisation of a collection of ciprofloxacin-resistant S. sonnei isolated
from within and outside Asia, aiming to explore the origins of this growing international
epidemic.
Methods
Ethics Statement
S. sonnei isolates from Bhutan, Thailand, and Vietnam were collected during diarrheal sur-
veillance studies [14]. IRB approval was granted for these studies (including organism char-
acterization) from the Research Ethics Board of Health (REBH), Ministry of Health, Bhutan
(Bhutan study), the Walter Reed Army Institute of Research (WRAIR) Institutional Review
Board, USA (Bhutan and Thailand studies), the Oxford Tropical Research Ethics Committee
(OxTREC), UK, and the Hospital for Tropical Diseases Ho Chi Minh City, Vietnam (Viet-
nam study). Written (Vietnam) or oral (Thailand and Bhutan) consent was obtained from a
parent or guardian at the time of enrolment into the study. The target patient groups for
these studies were generally hospitalised children aged less than 5 y residing in close proxim-
ity to the study centres. S. sonnei isolates from Cambodia were collected at the Angkor Hospi-
tal for Children (AHC) in Siem Reap province from the routine diagnostic laboratory; no
patient data were collected, and these organisms were not subject to local or international
IRB approval. The ciprofloxacin-resistant S. sonnei from countries outside Asia were col-
lected and characterized by the National Salmonella, Shigella, and Listeria monocytogenes
Reference Laboratory, Galway, Ireland, and the Microbiological Diagnostic Unit Public
Health Laboratory, Melbourne, Australia. These isolates were generally, but not exclusively,
obtained from patients reporting recent travel to countries with a high incidence of shigello-
sis in Asia (Table 1). As these isolates were from anonymous sources and collected at local
public health laboratories, these were not subject to IRB approval, and informed consent was
not required.
Strain Collection
Aiming to investigate the current international upsurge in ciprofloxacin-resistant S. sonnei in
detail, we gathered a collection of 60 contemporary ciprofloxacin-resistant S. sonnei from six
countries for whole-genome sequencing. The isolates originated from Asian countries with a
high incidence of shigellosis (Vietnam, n = 11; Bhutan, n = 12; Thailand, n = 1; Cambodia,
n = 1), as well as countries with a low incidence of shigellosis (Australia, n = 19; Ireland,
n = 16). Twelve additional ciprofloxacin-susceptible S. sonnei sequences from these settings
were also included for phylogenetic context. All strains were isolated independently between
2010 and 2015; details of the isolates used in this study are shown in Table 1.
Susceptibility to ciprofloxacin was determined by disk diffusion, E-test, agar dilution, or
broth microdilution, depending on the collaborating institution, and susceptibility breakpoints
were interpreted according to the European Committee on Antimicrobial Susceptibility Test-
ing (http://www.eucast.org/clinical_breakpoints). Namely, resistance was determined as strains
with a zone of inhibition<19 mm (5 μg disc) and/or a minimum inhibitory concentration
(MIC)>1 μg/ml against ciprofloxacin; the various location-specific methods and resulting
data are described in Table 1.
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Table 1. The origins of the Shigella sonnei isolates and sequences used in this study.
Country Isolates
in Central
Asia
clade (N)
Ciproﬂoxacin-
resistant
isolates (N)
Study or institute
origin
IRB approval or
public database
access
Patient group Region of
recent travel
history (N)
Sequencing
platform/
Public
database
Ciproﬂoxacin
susceptibility
Bhutan 12 12 Diarrhoeal disease
surveillance in
JDWNRHa,
Thimphu, Bhutan
(AFRIMSb)
The Research Ethics
Board of Health
(REBH), Ministry of
Health, Bhutan, and
the Walter Reed Army
Institute of Research
(WRAIR) Institutional
Review Board, USA
Hospitalised
children <5 y
old
NA Illumina HiSeq
2000
Disk diffusion/E-
test
Vietnam 11 11 Diarrhoeal disease
surveillance in Ho
Chi Minh City,
Vietnam (OUCRUc)
Oxford Tropical
Research Ethics
Committee (OxTREC),
UK, and the Hospital
for Tropical Diseases
Ho Chi Minh City,
Vietnam
Hospitalised
children <5 y
old
NA Illumina MiSeq Disk diffusion
Thailand 8 1 Diarrhoeal disease
surveillance in
Thailand (AFRIMS)
The Research Ethics
Board of Health
(REBH), Ministry of
Health, Bhutan, and
the Walter Reed Army
Institute of Research
(WRAIR) Institutional
Review Board, USA
Hospitalised
children <5 y
old
NA Illumina HiSeq
2000
Disk diffusion
Cambodia 1 1 Diarrhoeal disease
surveillance in Siem
Reap, Cambodia
(COMRUd)
Anonymous clinical
isolates collected as
part of routine
diagnosis—IRB
approval not required
Hospitalised
children <5 y
old
NA Illumina HiSeq
2000
Disk diffusion
Ireland 20 16 National Salmonella,
Shigella, and L.
monocytogenes
Reference
Laboratory, Galway,
Ireland
Anonymous clinical
isolates sent to public
health reference
laboratory—IRB
approval not required
Primarily
patients with
recent travel
history
India (9),
Germany (1),
Morocco (1),
No travel (5),
Unknown (4)
Illumina HiSeq
2000
Broth
microdilution
Australia 20 19 Microbiological
Diagnostic Unit
Public Health
Laboratory in
Melbourne, Australia
Anonymous clinical
isolates sent to public
health reference
laboratory—IRB
approval not required
Patients with
recent travel
history
India (15),
Cambodia
(3), Thailand
(1),
Southeast
Asia (1).
Illumina
NextSeq
Agar dilution
United
States
14 10 Genome Trackr;
Centre for Disease
Control and
Prevention, USA
Data accessed from
NCBI under the
BioProject accession
number PRJNA218110
Unknown Unknown Illumina MiSeq in silico
assessment of
QRDRe
mutations
a Jigme Dorji Wangchuk National Referral Hospital
b Armed Forces Research Institute of Medical Sciences
c Oxford University Clinical Research Unit
d Cambodia Oxford Medical Research Unit
e quinolone resistance-determining region
NA, Not applicable
doi:10.1371/journal.pmed.1002055.t001
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Genome Sequencing and Analysis
All isolated S. sonnei were subcultured and subjected to DNA extraction prior to whole-
genome sequencing on various Illumina platforms to produce pair-ended short read sequences;
the specific sequencing system and the resulting public database numbers are shown in
Table 1. We additionally included 14 S. sonnei sequences from the NCBI database under the
Bioproject accession number PRJNA218110. These organisms were isolated in the US and
deposited as part of the GenomeTrackr Project. All sequences were mapped to the S. sonnei
Ss046 reference sequence (Accession number: NC_007384) using SMALT (version 0.7.4), and
SNPs were called against the reference and filtered using SAMtools [21]. To contextualize all
ciprofloxacin-resistant S. sonnei within the global phylogeny, we appended our collection to
include 133 publicly available sequences from a previous global analysis (accession
ERP000182) [20]. Previously characterized mobile genetic elements and putative recombina-
tion (predicted using Gubbins) were removed [20], resulting in a gap-free alignment of 211
non-duplicate pseudo-whole genome sequences of 4,738 SNPs. A whole-genome phylogeny
was inferred from this alignment using RAxML v8.1.3 under the GTRGAMMA substitution
model, and sufficient bootstrap replicates were determined automatically using the extended
majority rule (MRE) bootstrap convergence criterion. Bootstrap values>75% signify strong
statistical support for a node within a maximum likelihood phylogeny, thus indicating that all
isolates falling within that lineage are highly likely to be linked in evolutionary history at a
more recent time than those falling outside of that lineage. In order to obtain a refined phyloge-
netic structure of the Central Asia clade, we applied the aforementioned approach to a set of 97
S. sonnei sequences (86 novel sequences and 11 historical sequences) belonging to this clade.
This resulted in an alignment of 1,121 SNPs, which was used for phylogenetic inference. De
novo assemblies were generated for each read set using Velvet and VelvetOptimiser, and read
sets were mapped back to each assembly [22]. A manually curated database based on ResFinder
[23] was mapped against each assembly to identify mobile resistance genetic determinants in
all ciprofloxacin-resistant strains.
Results
Fluoroquinolone-Resistant S. sonnei in a Global Context
We constructed a whole genome phylogeny of S. sonnei, incorporating sequences from 133
globally representative isolates and 86 novel isolates from Vietnam, Cambodia, Thailand, Bhu-
tan, Australia, Ireland, and the US. The novel sequences included 60 from ciprofloxacin-resis-
tant (MIC>1 μg/ml or zone of inhibition<19 mm) organisms and 26 from ciprofloxacin-
susceptible organisms (or of unknown ciprofloxacin susceptibility isolated in the US). The
related metadata for the bacterial isolates are shown in S1 Table. The overall tree topology
reflected the previously described global phylogenetic structure [20], confirming the presence
of four distinct lineages (I, II, III, and IV); lineage III was the most commonly represented and
the most widely geographically distributed (Fig 1A). All ciprofloxacin-resistant S. sonnei
formed a single, well-supported monophyletic clade within the Central Asian expansion of
lineage III (Central Asia III), an MDR group that is closely related but distinct from the Global
III clade (Fig 1A and 1B).
The Emergence of a Fluoroquinolone-Resistant S. sonnei Clone
We next performed a more detailed phylogenetic reconstruction of the Central Asia III clade,
incorporating sequence data from the 60 phenotypically ciprofloxacin-resistant isolates and 26
others (ciprofloxacin-susceptible or of unknown ciprofloxacin susceptibility), along with 11
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Fig 1. The phylogenetic structure of ciprofloxacin-resistant Shigella sonnei in an international context. A) Unrooted maximum likelihood
phylogeny of 211 globally representative S. sonnei, including 60 sequences from ciprofloxacin-resistant isolates (highlighted by the blue branches).
Major lineages are indicated by numbers (I, II, III, and IV) as defined in Holt et al. 2012, with clades Global III and Central Asia III within lineage III
highlighted. Horizontal scale bar indicates the number of nucleotide substitutions per site. B) Unrooted maximum likelihood phylogeny of Central Asia
III, composed of 97 S. sonnei sequences. Branch colours indicate region of isolation (where no travel history is confirmed) or region of recent travel
(where travel history was confirmed) according to the keys. For isolates with confirmed recent travel, a coloured circle at the tip indicates the region
where the isolate was collected (multiple coloured circles are indicative of multiple isolates). Labelled arrows indicate branches where the mutations
gyrA-S83L, gyrA-D87N, gyrA-D87G, and parC-S80I have arisen. Blue background shading denotes isolates exhibiting ciprofloxacin resistance
conferred by triple mutations (gyrA-S83L, parC-S80I, and gyrA-D87G [or gyrA-D87N]). Subpopulations A and B are highlighted in the darker blue
shaded areas, denoting clonal expansions in Southeast Asia and Europe/America, respectively. Numbers above major branches indicate bootstrap
support values, and horizontal scale bar denotes the number of nucleotide substitutions per site.
doi:10.1371/journal.pmed.1002055.g001
Spread of Ciprofloxacin-Resistant Shigella sonnei
PLOSMedicine | DOI:10.1371/journal.pmed.1002055 August 2, 2016 7 / 12
historical Central Asia III sequences sourced from our previous global study (Fig 1B) [20]. The
majority of the Central Asia III isolates carried more than three antimicrobial resistance genes,
encoding resistance to a wide range of first-line antimicrobials including tetracycline (tetA),
streptomycin (strAB), and co-trimoxazole (dfrA1 and sul2), as previously described [20]. No
plasmid-mediated quinolone resistance genes (qnr, qepA, oxqAB, aac(6’)lb-cr) were detected in
the sequences of any of the ciprofloxacin-resistant S. sonnei. We additionally examined the
genome sequences for mutations in the quinolone resistance-determining region (QRDR)
within the DNA gyrase gene (gyrA) and the topoisomerase IV gene (parC), the regions encod-
ing the target residues for fluoroquinolones. Overlaying these mutations on the phylogenetic
tree indicated that the gyrA-S83L mutation, the first sequential mutation that confers reduced
susceptibility against fluoroquinolones, has arisen independently within the Central Asia III
clade on at least four separate occasions (Fig 1B). Amongst the isolates examined here for the
first time, extensive resistance to ciprofloxacin can be attributed to a single clonal emergence
event, via the sequential accumulation of gyrA-S83L followed by parC-S80I and gyrA-D87G,
except for a single outlier isolated in Australia (Fig 1B). Strong bootstrap support at each of
these nodes suggests that these mutations were sequential lineage-defining events, with the
final gyrA-D87G mutation preceding the expansion and intercontinental dissemination of the
Central Asia III clade. These three QRDR mutations were also shared by ten phenotypically
uncharacterized S. sonnei from the US, thus providing genotypic evidence for ciprofloxacin
resistance. The single outlier isolate shares the gyrA-S83L and parC-S80I QRDR mutations of
the other ciprofloxacin-resistant isolates, but harbours gyrA-D87N rather than a gyrA-D87G,
and is within a closely related out-group of the major ciprofloxacin-resistant clone (Fig 1B).
South Asia as a Hub of Fluoroquinolone-Resistant S. sonnei
We additionally mapped the country of isolation and patient travel history onto the Central
Asia III phylogeny to investigate the geographical structure of the clade (Fig 1B). For the cipro-
floxacin-resistant S. sonnei isolated from countries with a low incidence of shigellosis (Ireland,
Australia, and US), and for which data on recent travel history was confirmed (27/45; 60%),
India was the most commonly reported travel destination (21/27; 78%). The majority of the
isolates associated with travel to India clustered closely with strains isolated in neighbouring
Bhutan. These data suggest that South Asia is a primary source of ciprofloxacin-resistant S.
sonnei that have increasingly been isolated both within and outside of Asia in recent years. Fur-
thermore, greater genetic diversity was observed within the South Asian S. sonnei than within
the other sampled countries (Fig 1B), suggesting that this region currently acts as the most
likely geographical source population.
Our data also show evidence of regional diversification of ciprofloxacin-resistant S. sonnei
within Asia. The phylogenetic structure is highly suggestive of a clonal expansion of ciprofloxa-
cin-resistant S. sonnei in Southeast Asia, specifically within Vietnam, as indicated by a long
branch with 100% bootstrap support (Fig 1B). We additionally noted that S. sonnei nested
within this clonal expansion were also isolated from travellers returning from countries includ-
ing Cambodia and Thailand, indicating that isolates from this lineage have spread widely
across Southeast Asia, as well as having been introduced into Australia on at least five separate
occasions. An additional well-supported subpopulation of ciprofloxacin-resistant S. sonnei, iso-
lated in Ireland (five individuals with no recent history of travel and one individual returning
from Germany) and the US, likely represents an extended chain of local transmission within
Europe and the US (Fig 1B). Alternatively, although less likely, this subpopulation could repre-
sent multiple importations and short-term local transmission of S. sonnei strains originating
from an unsampled source population. Whilst it was not possible to identify the geographical
Spread of Ciprofloxacin-Resistant Shigella sonnei
PLOSMedicine | DOI:10.1371/journal.pmed.1002055 August 2, 2016 8 / 12
source or extent of local transmission definitively, the isolates most closely related to this Euro-
pean/US subpopulation originated in India and Bhutan, again suggesting South Asia was the
most likely origin of this subpopulation. These two expansion events in Southeast Asia and
Europe/US indicate that this clone of ciprofloxacin-resistant S. sonnei is also capable of sus-
tained circulation upon introduction into new locations.
Discussion
Here we provide direct evidence for the ongoing global expansion of S. sonnei exhibiting new
and clinically relevant antimicrobial resistance profiles. What is more, as we can use phylogeo-
graphy in high resolution, we can link the reservoir of these organisms to a specific region.
Therefore, this study has significant implications for understanding the international traffick-
ing of antimicrobial-resistant bacterial pathogens from Asia. Furthermore, we suggest that, as a
single-serotype, human-adapted pathogen with a clonal population structure, S. sonnei serves
as a tractable model for understanding how Gram-negative antimicrobial resistant pathogens
are being regularly mobilised around the globe.
To our knowledge, this is the first study that has used whole-genome sequencing to examine
the emergence and global spread of ciprofloxacin-resistant S. sonnei. Our data show that all
sequenced extant ciprofloxacin-resistant S. sonnei, though sourced from disparate geographical
locations, belonged to a single clonal expansion of lineage III, with South Asia being the most
likely hub for its origin and spread. Our findings support previous hypotheses suggesting that
ciprofloxacin-resistant S. sonnei in industrialised countries is being imported from South Asia
[15,16]. A recent estimation of worldwide antimicrobial usage reported that India was the larg-
est consumer of antimicrobials in 2010 [24]. Additionally, the fluoroquinolones are ranked as
the most common antimicrobial prescribed for acute enteric diseases in India and Bangladesh
[25,26]. The intensive use of fluoroquinolones in a region where there are foci of high popula-
tion density and inconsistent access to good sanitation is likely to have contributed to emer-
gence of ciprofloxacin-resistant enteric bacteria, such as S. sonnei and Salmonella Typhi, on the
Indian subcontinent [19]. Global dissemination of these organisms is likely facilitated by the
volume of travel between these regions and other areas of the world.
Our new data highlight the limitations of current typing protocols for tracking S. sonnei. It
had been previously observed that some of the ciprofloxacin-resistant S. sonnei isolates in this
study (originating from Bhutan and Ireland) shared a similar XbaI pulsed field gel electropho-
resis (PFGE) pattern [14,15]. This pulsotype has been observed previously in India and Bangla-
desh [12,13,27–29], as well as in Canada [30], Belgium [31], and Japan [32], where the
association with ciprofloxacin resistance was inconsistent. However, PFGE in this context did
not offer sufficient granularity to link all of the isolates or provide sufficient resolution into the
regional evolution of S. sonnei. Our phylogenetic analyses show that this pulsotype is associated
with a phylogenetic lineage, supporting the notion that this pulsotype actually represents a
widespread and pervasive subclade of Central Asia III.
This work has limitations. First, the lack of historical organisms from South Asia restricts
our inference to only the current situation. Furthermore, additional contemporary organisms
from other settings would have improved our understanding of the current geographical
spread of this clonal group. Although the data included in this analysis was generated from
organisms sampled in diverse geographic locations, the majority of sequences were retrieved
from South Asia, Southeast Asia, Europe, Australia, and the Americas. It is possible, albeit
unlikely, that our study might have overlooked an undersampled population that may ulti-
mately act as an additional reservoir. This issue is inherent to all phylogeographical investiga-
tions and can potentially be overcome by global-scale prospective sampling to capture and
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characterize maximal global diversity. Notwithstanding these limitations, whole-genome
sequencing of these geographically disparate organisms, together with plausible epidemiologi-
cal links, has provided data at the highest resolution for deciphering the emergence and inter-
national spread of ciprofloxacin-resistant S. sonnei. Future studies interrogating extensive
spatial and temporal collections of ciprofloxacin-resistant S. sonnei, as well as the S. sonnei
diversity specific to South Asia prior to and during the emergence of antimicrobial resistance,
are essential to further elucidate the origins and epidemiological dynamics of these popula-
tions. These supplementary investigations will greatly aid our efforts in controlling the spread
of the current ciprofloxacin-resistant clone and to prevent future emergent antimicrobial-resis-
tant bacterial populations.
In conclusion, the international surge of ciprofloxacin-resistant S. sonnei clone poses a sub-
stantial global health challenge, and our data show this threat is not only manifested in spo-
radic cases from returning travellers but also the establishment of endemic transmission in
new settings. The latter is already evident in high shigellosis incidence areas such as Southeast
Asia. Therefore, integrative efforts from both the research community and public health
authorities should be prioritised to track, monitor, and prevent the international spread of this
key enteric pathogen.
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